Investigation of the Transformations of a Novel Anti-cancer Agent Combining HPLC, HPLC-MS and Direct ESI-HRMS Analyses

Overview

Journal Anal Bioanal Chem

Specialty Chemistry

Date 2009 Jul 31

PMID 19641906

Citations 1

Authors

Lutz F Tietze

Birgit Krewer

Holm Frauendorf

Affiliations

Soon will be listed here.

Abstract

One of the main problems of anti-cancer therapy is an insufficient differentiation between normal and malignant cells by the known anti-proliferant agents. The antibody-directed enzyme prodrug therapy is a promising approach for a selective treatment of cancer, in which a non-toxic prodrug is enzymatically converted into a highly cytotoxic drug at the surface of malignant cells by a targeted antibody-enzyme conjugate. The transformations and the stability of a very promising novel prodrug and its corresponding cytotoxic derivative were now investigated in detail by high-performance liquid chromatography (HPLC)-mass spectrometry (MS). In order to determine the time-dependent DNA alkylation efficiency and the sequence selectivity of the novel compounds, DNA binding studies using direct electrospray-Fourier transform ion cyclotron resonance-MS (ESI-FTICR-MS) have been performed. These measurements were accompanied by HPLC analyses followed by MS of the separated species to confirm the results of the direct ESI-FTICR-MS measurements. The sites of DNA alkylation could be identified unambiguously by the mass spectrometric fragmentation pattern of the alkylated oligodeoxynucleotides as well as by the results of HPLC followed by MS. A combination of all techniques applied led to a better understanding of the mode of action of the new therapeutics and might be used for an estimation of the cytotoxicity of different prodrugs and drugs since the alkylation efficiency correlates with the bioactivity of the compounds in cell culture investigations.

Citing Articles

Determination of the biological activity and structure activity relationships of drugs based on the highly cytotoxic duocarmycins and CC-1065.

Tietze L, Krewer B, von Hof J, Frauendorf H, Schuberth I Toxins (Basel). 2011; 1(2):134-50.

PMID: 22069536 PMC: 3202783. DOI: 10.3390/toxins1020134.

References

Tietze L, Krewer B . Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies. Anticancer Agents Med Chem. 2009; 9(3):304-25. DOI: 10.2174/1871520610909030304. View

Bagshawe K . Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Rev Anticancer Ther. 2006; 6(10):1421-31. DOI: 10.1586/14737140.6.10.1421. View

Eis P, Smith J, Rydzewski J, Case D, Boger D, Chazin W . High resolution solution structure of a DNA duplex alkylated by the antitumor agent duocarmycin SA. J Mol Biol. 1997; 272(2):237-52. DOI: 10.1006/jmbi.1997.1223. View

Boger D, SCHMITT H, Fink B, Hedrick M . Parallel synthesis and evaluation of 132 (+)-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) analogues of CC-1065 and the duocarmycins defining the contribution of the DNA-binding domain. J Org Chem. 2001; 66(20):6654-61. DOI: 10.1021/jo010454u. View

Kupchinsky S, Centioni S, Howard T, Trzupek J, Roller S, Carnahan V . A novel class of achiral seco-analogs of CC-1065 and the duocarmycins: design, synthesis, DNA binding, and anticancer properties. Bioorg Med Chem. 2004; 12(23):6221-36. DOI: 10.1016/j.bmc.2004.08.051. View

Bando T, Narita A, Sasaki S, Sugiyama H . Specific adenine alkylation by pyrrole-imidazole CBI conjugates. J Am Chem Soc. 2005; 127(40):13890-5. DOI: 10.1021/ja052412j. View

Beck J, Colgrave M, Ralph S, Sheil M . Electrospray ionization mass spectrometry of oligonucleotide complexes with drugs, metals, and proteins. Mass Spectrom Rev. 2001; 20(2):61-87. DOI: 10.1002/mas.1003. View

Martin D, Biles C, GERPHEIDE S, HANKA L, KRUEGER W, McGovren J . CC-1065 (NSC 298223), a potent new antitumor agent improved production and isolation, characterization and antitumor activity. J Antibiot (Tokyo). 1981; 34(9):1119-25. DOI: 10.7164/antibiotics.34.1119. View

Ichimura M, Ogawa T, Takahashi K, Kobayashi E, KAWAMOTO I, Yasuzawa T . Duocarmycin SA, a new antitumor antibiotic from Streptomyces sp. J Antibiot (Tokyo). 1990; 43(8):1037-8. DOI: 10.7164/antibiotics.43.1037. View

10.

Tietze L, Major F, Schuberth I, Spiegl D, Krewer B, Maksimenka K . Selective treatment of cancer: synthesis, biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 and the duocarmycins. Chemistry. 2007; 13(16):4396-409. DOI: 10.1002/chem.200700113. View

11.

Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn K . DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry. 1996; 35(41):13303-9. DOI: 10.1021/bi960306b. View

12.

Zhang Z, Poirier M . Cisplatin-DNA adduct determination in the hepatic albumin gene as compared to whole genomic DNA. Chem Res Toxicol. 1997; 10(9):971-7. DOI: 10.1021/tx970051i. View

13.

Smith J, Bifulco G, Case D, Boger D, Gomez-Paloma L, Chazin W . The structural basis for in situ activation of DNA alkylation by duocarmycin SA. J Mol Biol. 2000; 300(5):1195-204. DOI: 10.1006/jmbi.2000.3887. View

14.

Weimann A, Wickham G, Sheil M . Structural analysis of drug-DNA adducts by tandem mass spectrometry. Analyst. 2000; 125(4):627-33. DOI: 10.1039/a908920i. View

15.

Hurley L, Reynolds V, Swenson D, Petzold G, SCAHILL T . Reaction of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity. Science. 1984; 226(4676):843-4. DOI: 10.1126/science.6494915. View

16.

Tietze L, Feuerstein T . Enzyme and proton-activated prodrugs for a selective cancer therapy. Curr Pharm Des. 2003; 9(26):2155-75. DOI: 10.2174/1381612033454072. View

17.

Tietze L, Major F, Schuberth I . Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy. Angew Chem Int Ed Engl. 2006; 45(39):6574-7. DOI: 10.1002/anie.200600936. View

18.

Tietze L, Krewer B, Frauendorf H, Major F, Schuberth I . Investigation of reactivity and selectivity of DNA-alkylating duocarmycin analogues by high-resolution mass spectrometry. Angew Chem Int Ed Engl. 2006; 45(39):6570-4. DOI: 10.1002/anie.200600935. View

19.

Banoub J, Newton R, Esmans E, Ewing D, Mackenzie G . Recent developments in mass spectrometry for the characterization of nucleosides, nucleotides, oligonucleotides, and nucleic acids. Chem Rev. 2005; 105(5):1869-915. DOI: 10.1021/cr030040w. View

20.

Hofstadler S, Sannes-Lowery K, Hannis J . Analysis of nucleic acids by FTICR MS. Mass Spectrom Rev. 2004; 24(2):265-85. DOI: 10.1002/mas.20016. View